Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Irritable Bowel Syndrome

In brief

The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).

Key facts

Study ID
NCT04043455
Run by
Arena Pharmaceuticals
People needed
273
Starts
2019-07-24
Expected to finish
2021-04-29
Last updated by the study team
2025-01-30

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.